Introduction

Prostaglandin I2 (PGI), or prostacyclin, is one of the prostanoids, a group of local hormones that are best known for their roles in mediating inflammation. However, they also perform many other roles in maintaining homeostasis.[1][2] PGI2 acts as a vasodilator and a potent inhibitor of platelet aggregation.

Issues of Concern

Significant issues explored in this article include:

• Mechanism of COX-2 and IP
• PGI2's role in anti-platelet aggregation and preventing thrombosis
• Vasodilatory effects of PGI2 particularly in pulmonary arterial hypertension
• A corresponding increase in COX-1 activity during COX-2 inhibition

Cellular Level

All prostanoids share a common biosynthetic pathway. Phospholipase A releases arachidonic acid from the phospholipid membrane, after which cyclooxygenase (COX) enzymes and their bound synthase enzymes process the substrate into the various prostanoids. The prostanoid produced depends on metabolism by COX-1 or COX-2, which differentially express in tissues, and the respective synthase enzymes they bind.[2] 

Specifically, prostaglandin H2 is a substrate produced by both COX-1 and COX-2, but different attached synthase enzymes subsequently process it into the various prostanoids. COX-2 preferentially binds prostaglandin I synthase (PGIS) and some prostaglandin E synthase, while COX-1 binds thromboxane synthase, prostaglandin F synthase, and also prostaglandin E synthase. COX-2 is also controlled by inducible expression, while COX-1 is constitutive.[2]

Prostaglandin I2 is synthesized via COX-2 and PGIS from membrane phospholipids upon pro-inflammatory stimulation via cytokines, growth factors, or other physical and chemical exogenous stimuli.[3][4] PGI is primarily synthesized in vascular endothelial cells and smooth muscle cells but is also synthesized in fibroblasts, follicular dendritic cells, and thymic nurse cells.[3]

Development

PGI2 is primarily produced by endothelial and subendothelial cells, which both originate from the embryonic mesoderm.[3][5] In the late fetal and early postnatal stages, PGI2 acts as a key pulmonary vasodilator and also aids with the cardiopulmonary transition at birth and continuing development of the lung.[6]

Prostaglandins play an essential role in the closure of prenatal cardiac shunts[6]. Though not as significant as prostaglandin E2, prostaglandin I2 levels rise in preparation for birth.[6] Neonates born preterm also show reduced levels of prostanoids; this theoretically contributes to the increased rates of congenital defects such as patent ductus arteriosus in preterm infants.[7] Additionally, low dose prostaglandins can help to induce labor, particularly in overdue pregnancies.[8] Prostaglandin E2 and I2 are natural vascular relaxants, and inhibitors of their expression are useful as therapy to close patent ductus arteriosus in neonates.[7] The prostaglandin synthase inhibitor indomethacin or ibuprofen are commonly used for the treatment of symptomatic patent ductus artreriosus in preterm infants.[9]

Organ Systems Involved

PGI2 acts to promote vasodilation in vascular endothelial cells and pulmonary vessels. Hematologically, it also inhibits platelet aggregation, fibroblast proliferation, and leukocyte adhesion.[2][3] The IP receptor is expressed on multiple organs, kidney, liver, lung, and heart, and exerts anti-inflammatory effects in each of these locations.[10][11][12]

Function

Prostaglandin I2 plays many roles in the body, but its primary known functions are to inhibit platelet aggregation, affect smooth muscle relaxation and vasodilation, and limit immune cell proliferation.[3]

Mechanism

PGI2 binds to IP, a G protein-coupled receptor (GPCR) that is found primarily on the cell membranes of platelets and smooth muscle and some immune cells.[3] Like most GPCRs, IP is a seven-transmembrane-unit protein that becomes coupled to a G protein (guanosine nucleotide-binding alpha-stimulatory protein). Upon PGI2 binding, the G protein alpha subunit exchanges GDP for GTP and dissociates from the rest of the GPCR to activate adenylyl cyclase, which begins producing cAMP.[13] Elevated cAMP then causes phosphorylation of essential downstream proteins that eventually result in inhibition of platelet aggregation, smooth muscle relaxation, and reduced cell proliferation.

Related Testing

PGI2 has a half-life of 2 minutes and quickly metabolizes into 6-keto prostaglandin-F1 alpha, which can be found and measured in urine.[4][14] However, this measurement is not used clinically but only for research purposes.

While there have been a few studies looking at the link between polymorphisms of PTGS2, the gene for COX-2, and various pathologies, the results are still controversial, and no clinical use for these findings has yet been defined.[15]

Pathophysiology

Prostaglandin I2 and the COX-2 system is found widely in the body, so the effects of regulation are diverse, and many have not yet been adequately studied.[3] However, a few places of note are in pulmonary and cardiac vasculature, peripheral vasculature, and various immune cells.

The induction of the arachidonic acid pathway via inflammatory mediators is well-described: phospholipases (especially A2) cleave arachidonic acid from sources including the cellular membrane, and arachidonic acid is then acted on by cyclo-oxygenase enzymes that convert arachidonic acid to prostaglandins which enter circulation.[4][3]

Prostaglandin I2 is the most potent known natural inhibitor of platelet aggregation and found in most mammals that use platelet mediated thrombosis for blood clotting.[4] Therefore it is not a difficult logical step to understand its role in maintaining cardiovascular health, particularly in preventing thrombotic occlusions.[2] Prostaglandin I2 is not involved in the acute reversal of thrombosis, but rather, as inflammatory mediators increase in circulation in response to an insult or ruptured arteriosclerotic plaque, COX-2 enzymes are also upregulated and increase the production of prostaglandin I2. Increased production of prostaglandin I2 prevents platelet aggregation and decreases the risk of thrombosis, and because of increased expression in cardiac vasculature, particularly myocardial infarction.

Prostaglandin I2 also provides potent vasodilatory effects by acting on smooth muscle as a relaxant. COX-2 and its corresponding PGI-Synthase are upregulated in hypoxia to promote a vasodilatory response.[16] These receptors are found in increased levels in the pulmonary vasculature and are suspected of serving a protective role therein.[17]

Prostaglandin I2 also appears to play a regulatory role in immune cells, exerting a protective effect on organs from immune-mediated injury. However, many of these pathways have not been adequately explored.[3][11] While it is known that IP receptors express in fibroblasts, macrophages, dendritic cells, T regulatory cells, eosinophils, and neutrophils, the precise functions are not well known. One pathway that has been a target of extensive study is the allergic pathway, particularly in the lungs. During an allergic reaction, prostaglandin I2 is produced in the lungs, and they have correlations to limiting the responses of Th2 cells. Th2 cells are involved in the formation of a maladaptive allergic response, directing IgE class switching and secretion.[18]

Clinical Significance

Clinically, the two areas of interest in prostaglandin I2 function are selective inhibition of COX-2, thereby preventing PGI2 expression, and pharmacologic addition of PGI2.

Non-steroidal anti-inflammatory drugs, including aspirin, indomethacin, and ibuprofen, all inhibit COX enzymes non-selectively. Currently, however, celecoxib is one of the only approved drugs able to inhibit COX-2 selectively.[19] The effect profile of celecoxib includes not only inhibition of PGI2's vasodilatory and platelet aggregatory affects, but also increased the activity of COX-1. Generally, the upregulation of COX-1 involves an increased prothrombotic environment.[19]

Pharmacologic administration of PGI2 analogs is useful in pulmonary arterial hypertension, peripheral occlusive disease, and diabetic vascular complications.[3] Epoprostenol is a synthetic prostacyclin that can be given through parenteral administration and causes preferential vasodilation in the pulmonary vasculature, though effects occur in all vasculature.[17]

Additionally, several animal models have shown promising results for the use of inhaled iloprost in the treatment for asthma due to its immunomodulatory effects.[3]

It is important to realize that the dose of aspirin(acetylsalicylic acid), a prostaglandin synthase inhibitor have selective effects on the synthesis of thromboxane A2, a prothrombotic prostaglandin, and PGI2, a platelet anti-aggregating agent. Low dose aspirin inhibits more thromboxane A2 without much impact on PGI2, whereas a higher dose inhibits both. That is the main reason why low dose aspirin (such as 81 mg) rather than the high dose (such as 650 mg) is used clinically as antiplatelet therapy in medical practice.[20]

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Lang IM, Gaine SP. Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension. Eur Respir Rev. 2015 Dec;24(138):630-41. [PMC free article: PMC9487617] [PubMed: 26621977]

2.

Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011 May;31(5):986-1000. [PMC free article: PMC3081099] [PubMed: 21508345]

3.

Dorris SL, Peebles RS. PGI2 as a regulator of inflammatory diseases. Mediators Inflamm. 2012;2012:926968. [PMC free article: PMC3407649] [PubMed: 22851816]

4.

Kelton JG, Blajchman MA. Prostaglandin I2 (prostacyclin). Can Med Assoc J. 1980 Jan 26;122(2):175-9. [PMC free article: PMC1801769] [PubMed: 6988063]

5.

Evseenko D, Zhu Y, Schenke-Layland K, Kuo J, Latour B, Ge S, Scholes J, Dravid G, Li X, MacLellan WR, Crooks GM. Mapping the first stages of mesoderm commitment during differentiation of human embryonic stem cells. Proc Natl Acad Sci U S A. 2010 Aug 03;107(31):13742-7. [PMC free article: PMC2922221] [PubMed: 20643952]

6.

Shaul PW, Pace MC, Chen Z, Brannon TS. Developmental changes in prostacyclin synthesis are conserved in cultured pulmonary endothelium and vascular smooth muscle. Am J Respir Cell Mol Biol. 1999 Jan;20(1):113-21. [PubMed: 9870924]

7.

Coceani F, Olley PM. The control of cardiovascular shunts in the fetal and perinatal period. Can J Physiol Pharmacol. 1988 Aug;66(8):1129-34. [PubMed: 3052747]

8.

Rath W. [Paradigm shift in obsterics--the example of induction of labour]. Z Geburtshilfe Neonatol. 2008 Aug;212(4):147-52. [PubMed: 18729037]

9.

Meena V, Meena DS, Rathore PS, Chaudhary S, Soni JP. Comparison of the efficacy and safety of indomethacin, ibuprofen, and paracetamol in the closure of patent ductus arteriosus in preterm neonates - A randomized controlled trial. Ann Pediatr Cardiol. 2020 Apr-Jun;13(2):130-135. [PMC free article: PMC7331836] [PubMed: 32641884]

10.

Kumei S, Yuhki KI, Kojima F, Kashiwagi H, Imamichi Y, Okumura T, Narumiya S, Ushikubi F. Prostaglandin I₂ suppresses the development of diet-induced nonalcoholic steatohepatitis in mice. FASEB J. 2018 May;32(5):2354-2365. [PubMed: 29247122]

11.

Yin H, Cheng L, Langenbach R, Ju C. Prostaglandin I(2) and E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury. Hepatology. 2007 Jan;45(1):159-69. [PubMed: 17187424]

12.

Hui Y, Ricciotti E, Crichton I, Yu Z, Wang D, Stubbe J, Wang M, Puré E, FitzGerald GA. Targeted deletions of cyclooxygenase-2 and atherogenesis in mice. Circulation. 2010 Jun 22;121(24):2654-60. [PMC free article: PMC2909762] [PubMed: 20530000]

13.

Stitham J, Arehart EJ, Gleim SR, Douville KL, Hwa J. Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations. Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):95-108. [PubMed: 17164137]

14.

Jones RL, Watson ML. Vascular sensitivity to prostaglandin I2 and urinary excretion of 6-keto-prostaglandin F1 alpha in conscious dogs. Clin Sci (Lond). 1986 Nov;71(5):527-32. [PubMed: 3533394]

15.

Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F, Moreno V., Bellvitge Colorectal Cancer Study Group. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer. 2004 Jul 19;91(2):339-43. [PMC free article: PMC2409800] [PubMed: 15173859]

16.

Camacho M, Rodríguez C, Guadall A, Alcolea S, Orriols M, Escudero JR, Martínez-González J, Vila L. Hypoxia upregulates PGI-synthase and increases PGI₂ release in human vascular cells exposed to inflammatory stimuli. J Lipid Res. 2011 Apr;52(4):720-31. [PMC free article: PMC3284164] [PubMed: 21296955]

17.

"Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension." Irene M. Lang, Sean P. Gaine. Eur Respir Rev 2015; 24: 630-641. Eur Respir Rev. 2017 Jan;26(143) [PubMed: 28049123]

18.

Jaffar Z, Wan KS, Roberts K. A key role for prostaglandin I2 in limiting lung mucosal Th2, but not Th1, responses to inhaled allergen. J Immunol. 2002 Nov 15;169(10):5997-6004. [PubMed: 12421986]

19.

Bing RJ, Lomnicka M. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events? J Am Coll Cardiol. 2002 Feb 06;39(3):521-2. [PubMed: 11823092]

20.

Oláh L, Misz M, Bereczki D, Fekete I, Bordánné JE, Takács EI. [Low doses of acetylsalicylic acid effectively inhibits thrombocyte aggregation after ischemic stroke]. Orv Hetil. 1996 Mar 03;137(9):455-9. [PubMed: 8714038]